Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 2/20 | 0.37 |
| ▸ | PAK4 | O96013 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | PLK4 | O00444 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 3/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922274 | 0.90 | RET (0.41) | PAK1PAK4JAK2PLK4RET | |
| SCHEMBL5144275 | 0.87 | PDE10A (0.35) | PDE10AROCK2GSK3B | |
| SCHEMBL3926826 | 0.84 | RET (0.40) | PAK1PAK4JAK2PLK4RET | |
| SCHEMBL3922738 | 0.83 | PDE10A (0.35) | PDE10AROCK2GSK3B | |
| SCHEMBL3924292 | 0.83 | PDE10A (0.35) | PDE10AROCK2GSK3B | |
| SCHEMBL3934604 | 0.83 | PDCD1LG2 (0.34) | PDE10AROCK2GSK3B | |
| SCHEMBL3924561 | 0.83 | PDE10A (0.33) | PDE10AROCK2GSK3B | |
| SCHEMBL3935553 | 0.82 | PDE10A (0.36) | PDE10AROCK2GSK3B | |
| SCHEMBL3926958 | 0.82 | PIM1 (0.36) | — | |
| SCHEMBL3935098 | 0.82 | AOC3 (0.34) | JAK2PDE10AJAK3ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051980-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | PAK1 529/4885PAK4 837/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.